Senseonics (NYSE:SENS) this week announced that it partnered with Geo-Med to provide access to the Eversense continuous glucose monitor to more than 9 million veterans and U.S. government staff.
The company’s Eversense device is the first CGM system to feature an implantable sensor that can be worn for up to 90 days.
The system includes a small sensor that is implanted just below the skin in an in-office procedure. It continuously measures glucose levels, sending that data to a mobile app every five minutes and alerting users if their glucose levels drop out of range. The company’s wearable transmitter can also be removed, recharged and re-adhered without discarding the implanted sensor.
“We are pleased to partner with Geo-Med in providing veterans with diabetes access to the latest CGM technology available. This agreement gives veterans and Department of Defense personnel at military treatment facilities the ability to choose our Eversense CGM System to help manage their diabetes,” president & CEO Tim Goodnow said in prepared remarks. “Strategic partnerships like this serve to broaden access to Eversense for more patients. Further, consistent with our corporate values, we are proud to partner for growth with Geo-Med, a veteran-owned business.”
“We are proud to partner with companies like Senseonics to offer the latest CGM technology to our veterans,” Geo-Med CEO Mike Locke added. “Being a veteran myself, our mission is to deliver superior customer service, uncompromised product quality and business integrity for our nation’s finest at VA Medical Centers and Military Treatment Facilities all over the country. We are determined to provide the highest level of service to all those who served—past and present. This partnership is another example of us fulfilling our mission.”
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.